Slide 1: Future Proof Healthcare - Presentation Q3(22)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q3(22) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 3rd quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 3rd quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company 174 employees & consultants at quarter end V
Slide 4: Time to actionable results is important
Time to actionable results is important Sepsis is the most common cause of death in our hospitals More common than lung + prostate + breast-cancer combined Accounts for approximate 30% of all deaths in the hospital Most expensive condition to treat in the US. >27B USD1) Time to correct treatment is
Slide 5: Q-linea will be in control of marketing for all products
Q-linea will be in control of marketing for all products After discussions between the parties, a joint decision was taken to end distribution partnership. Thermo Fisher Scientific decided to refocus on its core media business. The view of ASTar has not changed and ASTar will be missed… Sales target
Slide 6: Why did we not meet the sales targets?
Why did we not meet the sales targets? We have analysed the launch in Europe and we have a couple of important lessons learned. Rapid antibiotic susceptibility testing (rAST) is a young field in Europe. The Corona pandemic has had continued effects during 2022 with stretched hospital budgets and lim
Slide 7: ASTar performance is strong and it is easy to use
ASTar performance is strong and it is easy to use Evaluation of commercial systems for rapid antimicrobial susceptibility testing (rAST) of positive blood cultures: Comparison of susceptibility results View Sheffield Hospital’s scientific poster presentation from ECCMID 2022, featuring the ASTar Sys
Slide 8: Our plan for short and long-term commercial success of ASTar
Our plan for short and long-term for commercial success of ASTar When launching a new product, we believe that a long-term strategy is important. Increase awareness of rAST Q-linea will actively support key opinion leaders and provide ASTar for evaluations. Q-linea is in late-stage discussions to st
Slide 9: Our planned approach to the market
Our planned approach to the market The collaboration with Thermo Fisher was a partnership, therefore Q-linea has mirrored Thermo Fishers sales & support organization and has participated during launch Q-linea currently have a strong commercial and clinical value team. 15 persons in the commercial or
Slide 10: Our planned approach to the market, cont.
Our planned approach to the market, cont. We have a strong product and are investigating extending sales capabilities with commercial partnerships. Q-linea has been approached by several large companies in the field within two days of the press release. Commercial partnership with Thermo Fisher incl
Slide 11: ASTar is coming closer to the US market & Q-linea is ready for the European market
ASTar is coming closer to the US market & Q-linea is ready for the European market Discussions are ongoing with FDA and Q-linea passed IVDR audit performed by Q-linea is currently awaiting feedback TÜV SÜD Typically, an FDA approval will take 12-18 months Certificate will be issued during 2023 FDA h
Slide 12: Podler discussions ongoing and capability build-up in production
Podler discussions ongoing and capability build-up in production Podler discussions are ongoing Q-linea is in discussions around a potential commercial collaboration regarding Podler. After changes in ASTar distribution, we are evaluating best commercial strategy for ASTar and Podler. Build up in pr
Slide 13: Key highlights after period end
Key highlights after period end ID week in Washington 19-23 October Rapid AST was one of the key themes of the conference. Antimicrobial Stewardship programs in the US much more broadly established and they see phenotypic rapid AST as one of the key needs to reduce time to optimal treatment. Compare
Slide 14: A pivotal development
A pivotal development Naturally, the separation from Thermo Fisher was not the plan, nor the intent when we enter the partnership two years ago. However, Q-linea will now be in full control the commercial direction for both ASTar and other products and interest from other companies is strong. It wil
Slide 15: Income statement third quarter
Income statement third quarter Net sales in the third quarter amounted to SEK 2.9 million (1.1). Operating result totalled SEK -58.9 million (-50.0). The company reported a loss after tax of SEK -59.4 million (-49.1). Earnings per share, before and after dilution amounted to SEK -2.03 (-1.68). Figur
Slide 16: Balance sheet items at the end of third quarter
Balance sheet items at the end of third quarter Cash and cash equivalents amounted to SEK 28.9 million (15.1) Total Short-term investments amounted SEK 65.3 million (150.9) which pertain of the current portion of non-current assets (listed bonds). Non-current assets, listed bonds SEK 63.2 million (1
Slide 17: Cash flow statement third quarter
Cash flow statement third quarter Cash flow from operating activities SEK -55.4 million (-63.0). Decrease in cash outflow from operating activities mainly due to favourable changes in the working capital compared to the same quarter last year which is partly offset by lower Operating result. Cash fl
Slide 18: Thank you
Looking forward to an exciting continuation of 2022 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 18